Jasper Therapeutics, Inc. (JSPR)
NCM – Real vaqt narxi. Valyuta: USD
1.05
-0.06 (-5.41%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.05
+0.00 (0.47%)
Bozordan keyin: Mar 27, 2026, 6:17 PM EDT

NCM – Real vaqt narxi. Valyuta: USD
1.05
-0.06 (-5.41%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.05
+0.00 (0.47%)
Bozordan keyin: Mar 27, 2026, 6:17 PM EDT
Jasper Therapeutics, Inc., klinik tadqiqot bosqichidagi biotexnologiya kompaniyasi, mast va gematopoez hujayralari tomonidan boshqariladigan kasalliklarni davolash uchun terapiya ishlab chiqishga qaratilgan. Kompaniyaning asosiy mahsulot nomzodi briquilimab bo'lib, u mast va ildiz hujayralaridagi CD117 retseptoriga bog'lanish va signal berish uchun ildiz hujayrasi omilini bloklash uchun mo'ljallangan monoklonal antiteladir. U surunkali spontan ürtiker, surunkali indüklenebilir ürtiker va astma, shuningdek, o'roqsimon hujayrali anemiya, Fanconi anemiyasi va og'ir kombinatsiyalangan immunitet tanqisligi bo'lgan bemorlarda ildiz hujayralari transplantatsiyasi uchun konditsioner vositalar kabi turli mast hujayralari tomonidan boshqariladigan kasalliklarga chalingan bemorlar uchun terapevtik vositalarni ishlab chiqish va tijoratlashtirishga qaratilgan. Jasper Therapeutics, Inc. 2018-yilda tashkil etilgan va Redwood City, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Alex Gray | Head of Investor Relations |
| Dr. Daniel C. Adelman M.D. | Acting Chief Medical Officer, Member of Scientific Advisory Board & Senior Clinical Advisor |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board & Director |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
| Mr. Herbert C. Cross CPA | CFO & Corporate Secretary |
| Mr. Jeetinder Singh Mahal M.B.A. | President, COO, CEO & Director |
| Mr. Matthew Ford | Senior Vice President of Human Resources |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-08 | 8-K | ea0272248-8k_jasper.htm |
| 2026-01-07 | 8-K | ea0271735-8k_jasper.htm |
| 2025-12-02 | 8-K | ea0268071-8k_jasper.htm |
| 2025-11-10 | 8-K | ea0264586-8k_jasper.htm |
| 2025-09-19 | 8-K | ea0258026-8k_jasper.htm |
| 2025-08-13 | 10-Q | ea0252091-10q_jasper.htm |
| 2025-07-09 | 8-K | ea0248394-8k_jasper.htm |
| 2025-07-07 | 8-K | ea0248252-8k_jasper.htm |
| 2025-07-03 | 8-K | ea0248135-8k_jasper.htm |
| 2025-06-16 | 8-K | ea0245793-8k_jasper.htm |
| Mr. Thomas G. Wiggans | Executive Chairman |
| Ms. Patricia Carlos | Senior Vice President of Regulatory Affairs & Quality |